IGF1R and breast carcinoma: Although more than 10 IGF/IGF1R inhibitors have entered clinical trials44, many large clinical trials involving patients with non-small-cell lung cancer, breast cancer, and pancreatic cancer failed to show significant clinical benefit45–47.